What Is Noopept?

Noopept, one of several nootropics created based on the structure of piracetam, was developed in 1996 by T. A. Gudasheva at the Zakusov Institute of Pharmacology, the Russian Academy of Medical Sciences. One of its metabolites, cycloprolylglycine (CPG) is heightened in the brain 1 hour after Noopept ingestion, & it’s this metabolite that’s considered to be responsible for the longer-term nootropic activities of the supplement.

CPG is an endogenous dipeptide having a wide range of psychotropic actions & putative therapeutic potential for depression. A small but increasing body of data indicates that the antidepressant-like effect of CPG is linked with neuroplastic modifications in the brain or 5-HT system modulation. Nonetheless, the mechanisms of the dipeptide action stay elusive [1].

Cycloprolylglycine is thought to heighten the levels of the brain-derived neurotrophic factor (BDNF) in the brain. Investigators consequently asserted that a nootropic based on cycloprolylglycine would have identical effects, & that is precisely what is proclaimed about Noopept.

As a supplement, it works by augmenting acetylcholine signaling in the brain. Concurrently, it promotes the production of nerve growth factor (NGF) & also BDNF in the hippocampus, thus protecting the brain against glutamate toxicity. When there is high glutamate, it overexcites the nerve cells & destroys them quickly in a mechanism called excitotoxicity. It also augments inhibitory neurotransmission in the brain.

Certainly, Noopept is an influential synthetic nootropic with cognitive enhancement & neuroprotective effects. Because of this, it continues to be used for treating various cognitive disorders, including traumatic brain injury, cerebral vascular insufficiency, attention deficit hyperactivity disorder (ADHD), & age-affiliated cognitive decline.